Comparing the cost-effectiveness of rituximab maintenance and radioimmunotherapy consolidation versus observation following first-line therapy in patients with follicular lymphoma

Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
Qiushi ChenChristopher R Flowers

Abstract

Phase 3 randomized trials have shown that maintenance rituximab (MR) therapy or radioimmunotherapy (RIT) consolidation following frontline therapy can improve progression-free survival for patients with follicular lymphoma (FL), but the cost-effectiveness of these approaches with respect to observation has not been examined using a common modeling framework. To evaluate and compare the economic impact of MR and RIT consolidation versus observation, respectively, following the first-line induction therapy for patients with advanced-stage FL. We developed Markov models to estimate patients' lifetime costs, quality-adjusted life-years (QALYs), and life-years (LYs) after MR, RIT, and observation following frontline FL treatment from the US payer's perspective. Progression risks, adverse event probabilities, costs, and utilities were estimated from clinical data of Primary RItuximab and MAintenance (PRIMA) trial, Eastern Cooperative Oncology Group (ECOG) trial (for MR), and First-line Indolent Trial (for RIT) and the published literature. We evaluated the incremental cost-effectiveness ratio for direct comparisons between MR/RIT and observation. Model robustness was addressed by one-way and probabilistic sensitivity analyses. Compar...Continue Reading

References

Oct 1, 1993·Medical Decision Making : an International Journal of the Society for Medical Decision Making·F A Sonnenberg, J R Beck
Jan 19, 2000·Medical Decision Making : an International Journal of the Society for Medical Decision Making·C C EarleG A Wells
Mar 2, 2005·International Journal of Technology Assessment in Health Care·Cynthia P IglesiasUNKNOWN NEVALAT Project Group
Aug 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John P LeonardStanley J Goldsmith
Sep 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Beverly A GuadagnoloAndrea K Ng
Jun 27, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B D Cheson
Oct 16, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Franck MorschhauserAnton Hagenbeek
Oct 29, 2008·Hematology/oncology Clinics of North America·Daryl Tan, Sandra J Horning
Nov 5, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Samuel A JacobsThe Minh Luong
Mar 4, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Howard HochsterSandra J Horning
Apr 1, 2005·Expert Review of Pharmacoeconomics & Outcomes Research·John W TumehChristopher R Flowers
Jan 15, 2010·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Joshua A RayRobert Marcus
May 12, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tim Martin Illidge
Dec 16, 2010·Clinical Lymphoma, Myeloma & Leukemia·Christopher R Flowers, James O Armitage
Jun 11, 2011·Best Practice & Research. Clinical Haematology·Marinus H J van Oers, Marie José Kersten
Mar 31, 2012·Clinical Therapeutics·Erkki J SoiniTapio Nousiainen
Sep 20, 2012·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Andrew H BriggsUNKNOWN ISPOR-SMDM Modeling Good Research Practices Task Force
Sep 25, 2012·American Journal of Hematology·Arnold Freedman
Dec 13, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Oliver W PressRichard I Fisher
Aug 13, 2013·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·A Hagenbeek
Jan 10, 2014·European Journal of Haematology·Hedwig M BlommesteinCarin A Uyl-de Groot

❮ Previous
Next ❯

Citations

Aug 21, 2015·Future Oncology·Ashley D StatonChristopher R Flowers
Jun 3, 2015·Current Treatment Options in Oncology·Patrick M Reagan, Jonathan W Friedberg
Jun 20, 2017·Cancer Treatment Reviews·Lu ZhangChaitra Ujjani
Oct 7, 2017·Advances in Therapy·Gilles SallesDavid G Maloney
Jul 12, 2018·European Journal of Haematology·Eva U SpuktiAndrea Kerkhoff
Mar 12, 2019·Journal of Comparative Effectiveness Research·Jinma RenAaron Galaznik
Dec 15, 2015·Oncotarget·Patrizia MondelloMichael Mian
Nov 22, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Qiushi ChenJagpreet Chhatwal
Apr 22, 2017·Cancer Research·Damian J Green, Oliver W Press
Mar 10, 2021·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Gursharan K SohiNatalie G Coburn
May 4, 2021·Expert Review of Pharmacoeconomics & Outcomes Research·Ziyan ChenVakaramoko Diaby
Apr 22, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C CasuloC R Flowers
Dec 6, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R KarmaliE Zucca
Jul 18, 2021·PharmacoEconomics·Caitlin EichtenRichard T Maziarz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.